Skip to content

Evaluation of Comfilcon A and Senofilcon A Lenses

Clinical Comfort Evaluation of Biofinity and Acuvue Oasys Lenses

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01695369
Enrollment
61
Registered
2012-09-28
Start date
2012-08-31
Completion date
2012-08-31
Last updated
2020-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Brief summary

Evaluation of Comfilcon A and Senofilcon A Lenses

Detailed description

Non-dispensing, single-masked, randomized, contralateral study comparing the test lens against the control lens. Each subject will be randomized to wear the test lens in one eye and the control lens in the other eye.

Interventions

DEVICESenofilcon A; Comfilcon A

Senofilcon A; Comfilcon A

DEVICEComfilcon A; Senofilcon A

Comfilcon A; Senofilcon A

Sponsors

CooperVision, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Subjects must satisfy the following conditions prior to inclusion in the study: * Has had an oculo-visual examination in the last two years * Is at least 18 years of age and has full legal capacity to volunteer * Has read and understood the information consent letter * Is willing and able to follow instructions and maintain the appointment schedule * Is correctable to a visual acuity of 20/30 or better (in each eye) with their habitual vision correction * Currently wears soft contact lenses at least 3 days a week, 8 hours a day * Has clear corneas and no active ocular disease * Has not worn lenses for at least 12 hours before the examination * Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having: * No amblyopia * No evidence of lid abnormality or infection (e.g. entropion, ectropion, chalazia, recurrent styes) * No clinically significant slit lamp findings (e.g. infiltrates or other slit lamp findings Grade 2 or above: corneal edema, tarsal abnormalities, and conjunctival injection). * No other active ocular disease (e.g. glaucoma, history of recurrent corneal erosions, cornea \[infiltrates\], conjunctiva, lids, and intraocular infection or inflammation of an allergic, bacterial, or viral etiology) * No aphakia * Has prescription to match the available power range.

Exclusion criteria

Any of the following will render a subject ineligible for inclusion: * Greater than 0.75 of refractive astigmatism in either eye * Has never worn contact lenses before * Wears contact lenses on an extended wear basis * Has any systemic disease affecting ocular health * Is a known sufferer of ocular allergies * Is taking medication, such as oral antihistamines, antihistamine eye drops, oral and ophthalmic beta-adrenergic blockers (e.g. Propanolol, Timolol), anticholinergics, oral steroids and any prescribed or over-the-counter eye medication, except artificial tears or eye lubricants * Has any clinically significant lid or conjunctival abnormalities, neovascularization, corneal scars or corneal opacities * Is aphakic * Has undergone corneal refractive surgery. * Is wearing monovision * Is participating in any other type of clinical or research study * Female who is currently pregnant or is breast-feeding * Has \> grade 1 ocular corneal staining in both type and extent by \> grade 2 in either type or extent

Design outcomes

Primary

MeasureTime frameDescription
Subjective Responses for Comfort Rated on a 0-100 Visual Scale.Baseline Insertion, 10 Minutes, 5 hours and 10 hoursSubjective Patient Ratings measured using a Visual Analog Scale on a 0-100. (0=Cannot be worn. Causes pain, 20=Frequently irritating, 40=Occasionally irritating, 60=Occasionally noticeable but not irritating, 80=Rarely noticeable, 100=Cannot be felt ever)

Countries

United States

Participant flow

Pre-assignment details

Each subject will be randomized to wear the test lens in one eye and the control lens in the other eye. The subject is expected to attend the baseline visit not wearing their habitual contact lens products for at least 12 hours.

Participants by arm

ArmCount
Overall Study Participants
Senofilcon A and Comfilcon A
61
Total61

Baseline characteristics

CharacteristicOverall Study Participants
Age, Continuous26 years
STANDARD_DEVIATION 6
Age, Customized
<=18 years
0 eyes
Age, Customized
>=65 years
0 eyes
Age, Customized
Between 18 and 65 years
61 eyes
Region of Enrollment
United States
61 participants
Sex: Female, Male
Female
38 Participants
Sex: Female, Male
Male
23 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 610 / 61
serious
Total, serious adverse events
0 / 610 / 61

Outcome results

Primary

Subjective Responses for Comfort Rated on a 0-100 Visual Scale.

Subjective Patient Ratings measured using a Visual Analog Scale on a 0-100. (0=Cannot be worn. Causes pain, 20=Frequently irritating, 40=Occasionally irritating, 60=Occasionally noticeable but not irritating, 80=Rarely noticeable, 100=Cannot be felt ever)

Time frame: Baseline Insertion, 10 Minutes, 5 hours and 10 hours

ArmMeasureGroupValue (MEAN)Dispersion
Comfilcon ASubjective Responses for Comfort Rated on a 0-100 Visual Scale.Baseline Insertion86 units on a scaleStandard Deviation 15
Comfilcon ASubjective Responses for Comfort Rated on a 0-100 Visual Scale.10 Minutes89 units on a scaleStandard Deviation 14
Comfilcon ASubjective Responses for Comfort Rated on a 0-100 Visual Scale.5 Hours83 units on a scaleStandard Deviation 19
Comfilcon ASubjective Responses for Comfort Rated on a 0-100 Visual Scale.10 Hours79 units on a scaleStandard Deviation 23
Senofilcon ASubjective Responses for Comfort Rated on a 0-100 Visual Scale.10 Hours81 units on a scaleStandard Deviation 21
Senofilcon ASubjective Responses for Comfort Rated on a 0-100 Visual Scale.Baseline Insertion87 units on a scaleStandard Deviation 13
Senofilcon ASubjective Responses for Comfort Rated on a 0-100 Visual Scale.5 Hours84 units on a scaleStandard Deviation 18
Senofilcon ASubjective Responses for Comfort Rated on a 0-100 Visual Scale.10 Minutes91 units on a scaleStandard Deviation 12

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026